CN105381313A - Vitamin D composition and application thereof - Google Patents
Vitamin D composition and application thereof Download PDFInfo
- Publication number
- CN105381313A CN105381313A CN201510974074.XA CN201510974074A CN105381313A CN 105381313 A CN105381313 A CN 105381313A CN 201510974074 A CN201510974074 A CN 201510974074A CN 105381313 A CN105381313 A CN 105381313A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- compositions
- composition
- juice
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940046008 vitamin d Drugs 0.000 title claims abstract description 53
- 229930003316 Vitamin D Natural products 0.000 title claims abstract description 32
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 title claims abstract description 32
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 235000019166 vitamin D Nutrition 0.000 title claims abstract description 32
- 239000011710 vitamin D Substances 0.000 title claims abstract description 32
- 150000003710 vitamin D derivatives Chemical class 0.000 title claims abstract description 32
- 239000000843 powder Substances 0.000 claims abstract description 20
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 19
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 244000017020 Ipomoea batatas Species 0.000 claims abstract description 7
- 235000002678 Ipomoea batatas Nutrition 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims abstract description 5
- 235000012054 meals Nutrition 0.000 claims abstract description 4
- 238000001694 spray drying Methods 0.000 claims abstract description 4
- 241000628997 Flos Species 0.000 claims description 16
- 235000005739 manihot Nutrition 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 6
- 230000008020 evaporation Effects 0.000 claims description 6
- 235000013360 fish flour Nutrition 0.000 claims description 6
- UOELMDIOCSFSEN-FVZZCGLESA-N 7-Dehydrositosterol Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)C=C[C@H](C)C(C)C)=CC=C1C[C@@H](O)CCC1=C.C1[C@@H](O)CCC2(C)C(CC[C@@]3([C@@H]([C@H](C)C=C[C@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 UOELMDIOCSFSEN-FVZZCGLESA-N 0.000 claims description 3
- 230000029087 digestion Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 241000221022 Manihot Species 0.000 claims 5
- 230000000694 effects Effects 0.000 abstract description 9
- 230000003203 everyday effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 240000004507 Abelmoschus esculentus Species 0.000 abstract 1
- 241000251468 Actinopterygii Species 0.000 abstract 1
- 244000153885 Appio Species 0.000 abstract 1
- 235000010591 Appio Nutrition 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 235000013312 flour Nutrition 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 23
- 240000003183 Manihot esculenta Species 0.000 description 11
- 238000003304 gavage Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 7
- 230000004792 oxidative damage Effects 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 4
- 229930186217 Glycolipid Natural products 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000001889 Acid-Base Imbalance Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- MWKXCSMICWVRGW-UHFFFAOYSA-N calcium;phosphane Chemical compound P.[Ca] MWKXCSMICWVRGW-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100000244 chromosomal damage Toxicity 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003927 comet assay Methods 0.000 description 1
- 231100000170 comet assay Toxicity 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Marine Sciences & Fisheries (AREA)
- Inorganic Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of drug preparation and application and relates to a vitamin D composition and application thereof. The vitamin D composition is prepared from, by weight, 10-50% of vitamin D, 10-20% of celery root powder,5-15% of okra juice, 1-5% of oat flour, 10-60% of purple sweet potato powder,1-5% of fish mealand 0.5% of salt, wherein the total amount of the raw material is 100%. After the raw materials are mixed by adopting an existing spray drying method, powdery capsules are prepared, the weight of each capsule is 0.3-1.0 micrograms, the vitamin D content of per gram of the vitamin D composition is not less than 200 micrograms, and the vitamin D composition is used for improving the genetic material stability of diabetes. An adult takes 1 to 3 capsules every day and takes the capsules after half an hour after meal. The raw materials are easy to obtain, a preparation process is mature, a preparation method is easy to control, and the vitamin D composition is obvious in curative effect, free of toxic and side effects, safe, reliable and low in processing cost and is environmentally friendly.
Description
Technical field:
The invention belongs to medicine preparation and application technical field, relating to a kind of vitamin d compositions for improving diabetics hereditary material stability, by controlling the consumption of vitamin D, improving the stability of diabetics hereditary material, reduce DNA oxidative damage.
Background technology:
Diabetes are one group take hyperglycemia as the chronic metabolic disease of feature caused by defect of insulin secretion and/or insulin action obstacle, it is the disease of serious harm public health popular in global range, persistent high blood sugar and long-term metabolic disorder etc. can cause body tissue's organ, particularly eye, kidney, cardiovascular and neural infringement and dysfunction thereof and exhaustion, severe patient can cause dehydration, the acute complications such as electrolyte disturbance and acid base imbalance ketoacidosis and Hyperosmotic coma, and increasing research shows glucose-lipid metabolism disorder in diabetics body, free radical produces and increases, cause oxidative stress pressure increase, when antioxidant system in body can not remove too much oxidation material in time, DNA oxidative damage will be caused, and DNA oxidative damage can form the akinetic chromosome fragment causing micronucleus to produce, under this means high sugared environment, micronuclear rates also increases.
Vitamin D (VD) is the hormone of a kind of important adjustment calcium phosphorus balance and lipid metabolism, VD is except these common functions, also has some other function, as regulated and controled glycolipid metabolism and insulin resistant, immunomodulating and reducing oxidative stress pressure, research proves that VD state and glycolipid metabolism and insulin resistant are closely related, even relevant with genetic polymorphism, VD can strengthen immune function by the release strengthening congenital and adaptive immunoreactive activity and cytokine.According to current paper, the natral plant ingredients such as root of Herba Apii graveolentis, Flos abelmoschi manihot and Rhizoma Dioscoreae esculentae have service hoisting effect to vitamin D, especially diabetics are had to the effect alleviating the state of an illness.In recent years, the function of VD to diabetics glycolipid metabolism and suppression chromosome and DNA damage aspect obtains increasing concern.But on the impact of diabetics hereditary material stability, there is not been reported about VD.
Summary of the invention:
The object of the invention is to the shortcoming overcoming prior art existence, seeking to design provides a kind of vitamin d compositions for improving diabetics hereditary material stability, the glycolipid metabolism of diabetics can be regulated, reduce the oxidative stress pressure of diabetics, reduce DNA oxidative damage and micronuclear rates, maintain the stability of hereditary material.
To achieve these goals, in vitamin d compositions of the present invention, the percentage by weight of each composition is: vitamin D1 0-50%, root of Herba Apii graveolentis powder 10-20%, Flos abelmoschi manihot juice 5 ~ 15%, oatmeal 1-5%, purple sweet potato powder 10-60%, fish flour 1-5%, Sal 0.5%, the total amount of each raw material is 100%; Adopt existing spray drying method will to make the Powdered capsule of every heavy 0.3-1.0g after each raw material mixing, 200 μ g are no less than containing vitamin D in every gram of vitamin d compositions, for improving diabetes hereditary material stability, adult is 1 ~ 3 capsules daily, takes after half an hour after the meal.
The vitamin D that the present invention relates to, oatmeal, fish flour and Sal all adopt commercially available prod; The preparation technology of root of Herba Apii graveolentis powder is: squeezing the juice and filter after first being cleaned by fresh root of Herba Apii graveolentis obtains filtered juice, again filtered juice is carried out evaporation drying, first at 0 ~ 20 DEG C of temperature, temperature after evacuation, is made to rise to 20 DEG C ~ 37 DEG C, obtain drying solid through 24 ~ 18 hours after evacuation evaporation drying, then grind to form 100-150 object powder.
Flos abelmoschi manihot juice preparation technology of the present invention is: cleaned up by fresh Flos abelmoschi manihot, put into 80-100 DEG C of boiled water digestion 10-15 minute, put into 3-10 DEG C of cold water after pulling out immediately to soak and pull out again for 3-5 minute, then adopt prior art to be undertaken squeezing and filter and to obtain Flos abelmoschi manihot juice by the weight ratio of Flos abelmoschi manihot and pure water 1:1.
Purple sweet potato powder of the present invention is that light violet Rhizoma Dioscoreae esculentae is cut into 3-5mm lamellar, after temperature control 20-45 DEG C dries naturally, grinds into 100-150 object powder.
Compared with prior art, its raw material is easy to get, mature preparation process, and preparation method is easily controlled in the present invention, and curative effect is obvious, and have no side effect, safe and reliable, processing cost is low, edible environmental friendliness.
Accompanying drawing illustrates:
Fig. 1 is the induced DNA damage figure that the embodiment of the present invention 3 respectively organizes rat.
Fig. 2 is the micronucleus aspect graph of the embodiment of the present invention 3 diabetes rat.
Detailed description of the invention:
Below by embodiment, also the invention will be further described by reference to the accompanying drawings.
Embodiment 1:
In vitamin d compositions described in the present embodiment, the percentage by weight of each composition is: vitamin D1 0-50%, root of Herba Apii graveolentis powder 10-20%, Flos abelmoschi manihot juice 5 ~ 15%, oatmeal 1-5%, purple sweet potato powder 10-60%, fish flour 1-5%, Sal 0.5%, the total amount of each raw material is 100%; Adopt existing spray drying method will to make the Powdered capsule of every heavy 0.3-1.0g after each raw material mixing, 200 μ g are no less than containing vitamin D in every gram of vitamin d compositions, for improving diabetes hereditary material stability, adult is 1 ~ 3 capsules daily, takes after half an hour after the meal.
The vitamin D that the present embodiment relates to, oatmeal, fish flour and Sal all adopt commercially available prod; The preparation technology of root of Herba Apii graveolentis powder is: squeezing the juice and filter after first being cleaned by fresh root of Herba Apii graveolentis obtains filtered juice, again filtered juice is carried out evaporation drying, first at 0 ~ 20 DEG C of temperature, temperature after evacuation, is made to rise to 20 DEG C ~ 37 DEG C, obtain drying solid through 24 ~ 18 hours after evacuation evaporation drying, then grind to form 100-150 object powder.
Flos abelmoschi manihot juice preparation technology described in the present embodiment is: cleaned up by fresh Flos abelmoschi manihot, put into 80-100 DEG C of boiled water digestion 10-15 minute, put into 3-10 DEG C of cold water after pulling out immediately to soak and pull out again for 3-5 minute, then adopt prior art to be undertaken squeezing and filter and to obtain Flos abelmoschi manihot juice by the weight ratio of Flos abelmoschi manihot and pure water 1:1.
Purple sweet potato powder described in the present embodiment is that light violet Rhizoma Dioscoreae esculentae is cut into 3-5mm lamellar, after temperature control 20-45 DEG C dries naturally, grinds into 100-150 object powder.
Embodiment 2: manufacture diabetes rat model
The present embodiment chooses SPF level SD male rat 100, body weight is between 180g ~ 220g, normal nursing is random packet matched group and modeling group two groups after one week, wherein matched group (12) is fed not containing the normal feedstuff of vitamin D, modeling group (88) feeds the high glucose and high fat feedstuff containing 68.5% normal feedstuff, 20% sucrose, 10% Adeps Sus domestica and 1% cholesterol, after feeding 4 weeks, to modeling group rat limosis lumbar injection streptozotocin (STZ) 35mg/kg, the sodium citrate buffer solution that matched group injection is mutually commensurability; After injection, 24h and 72h surveys rat fasting blood-glucose, and twice equal > 11.1mmol/L's of blood glucose is modeling success; 88 rats modelings success 80 altogether in the present embodiment, modeling success rate is 91%, in experimentation, and all rats freely drink water, diet and being consistent before.
Embodiment 2:
The successful rat of modeling in embodiment 2 is divided into 5 groups by blood glucose by the present embodiment at random, often organize 16, the vitamin d compositions described in embodiment 1 is dissolved in soybean oil, every day is by each group of dosage gavage, the laggard rower of continuous gavage 6 weeks this collection and detection and statistical disposition, dosage is respectively:
N (Normal group, the vitamin d compositions of gavage physiological dose): 36IU/kg body weight;
DM (diabetic model group, the vitamin d compositions of gavage physiological dose): 36IU/kg body weight;
5N (diabetic groups, gavage 5 times of vitamin d compositions): 180IU/kg body weight;
25N (diabetic groups, gavage 25 times of vitamin d compositions): 900IU/kg body weight;
125N (diabetic groups, gavage 125 times of vitamin d compositions): 4500IU/kg body weight;
200N (diabetic groups, gavage 200 times of vitamin d compositions): 7200IU/kg body weight;
(1) collection of specimen and detection: gavage the 6th weekend, detect rat fasting blood-glucose, rat artery blood, femur and each internal organs are got after putting to death rat, be separated rat blood serum, detect blood biochemistry index, detect rat peripheral blood lymphocytes DNA damage with existing Comet Assay, and micronucleus test detection rat bone marrow cell micronuclear rates is carried out to rat marrow;
(2) statistical disposition: adopt SPSS17.0 statistical software to carry out one factor analysis of variance to the data collected, data are normal distribution, represent by mean ± standard deviation, data compare between two is undertaken by LSD method, with p < 0.05 for having statistical significance; 6 groups of rat statistical analysiss the results are shown in Table 1 and table 2, as shown in Table 1, spontaneous DNA oxidative damage is 5N (57 ± 17.327) group and 25N group (76.75 ± 25.559) reduction (p < 0.05) more remarkable in model group (113.5 ± 55.514), and 5N group (57 ± 17.327) does not have significant difference compared with N group (45.4 ± 14.524), prove that 5N group significantly can reduce the spontaneous DNA oxidative damage of diabetes rat, and make it close to normal level, and 125N and 200N does not observe similar effect; When with 10 μm of ol/lH
2o
2. during induced DNA damage, each intervention group (5N:166.88 ± 59.977 of VD; 25N:174.50 ± 86.761; 125N:192.67 ± 34.737; 200N:212.14 ± 90.744) and DM group (206.63 ± 65.968) between compare and there is no significant significant difference, but 5N, 25N group does not have significant difference compared with N group, proving that the VD of 5 times and 25 times intervenes can make DNA bring out damage close to normal level, appropriate VD supplements can obviously reduce rat bone marrow cell micronuclear rates, 5N, 25N, 125N group rat micronuclear rates comparatively DM group rat marrow micronuclear rates obviously reduces, difference has statistical significance (p < 0.05), and 200N group does not observe similar effect, refer to table 2.It can thus be appreciated that appropriate VD supplements can by reducing spontaneous DNA oxidative damage and reducing the hereditary stability that micronuclear rates improves DM rat.
Table 1: various dose vitamin D is on the impact of each group of DNA damage in rats
A: compared with N, p < 0.05; B: compared with 5N; C: compared with 5N, p < 0.05.
Table 2: vitamin D is on the impact of each group of rat micronuclear rates
A: compared with N, p < 0.05; B: p < 0.05 compared with DM; C: compared with 5N, p < 0.05; D: compared with 25N, p < 0.05; E: compared with 125N, p < 0.05.
Embodiment 4:
The VD compositions that embodiment 1 is prepared by the present embodiment is used for part of diabetes mellitus patient, adult's diabetics 80 people, divide for each person every day and take VD compositions for three times and amount to 0.9-3 gram, take 2-3 month continuously, contrast take before and after result show, 23 people's state of an illness are clearly better, and 45 people take a turn for the better index, increase the weight of without case, illustrate that product of the present invention has the effect improving diabetic condition.
Claims (6)
1. a vitamin d compositions, is characterized in that the percentage by weight of each composition is: vitamin D1 0-50%, root of Herba Apii graveolentis powder 10-20%, Flos abelmoschi manihot juice 5 ~ 15%, oatmeal 1-5%, purple sweet potato powder 10-60%, fish flour 1-5%, Sal 0.5%, the total amount of each raw material is 100%; Adopting existing spray drying method by making the Powdered capsule of every heavy 0.3-1.0g after each raw material mixing, in every gram of vitamin d compositions, being no less than 200 μ g containing vitamin D.
2., according to claim 1 vitamin d compositions, it is characterized in that described vitamin D, oatmeal, fish flour and Sal all adopt commercially available prod.
3. according to claim 1 vitamin d compositions, it is characterized in that the preparation technology of described root of Herba Apii graveolentis powder is: squeezing the juice and filter after first being cleaned by fresh root of Herba Apii graveolentis obtains filtered juice, again filtered juice is carried out evaporation drying, first at 0 ~ 20 DEG C of temperature, temperature after evacuation, is made to rise to 20 DEG C ~ 37 DEG C, obtain drying solid through 24 ~ 18 hours after evacuation evaporation drying, then grind to form 100-150 object powder.
4. according to claim 1 vitamin d compositions, it is characterized in that the preparation technology of described Flos abelmoschi manihot juice is: cleaned up by fresh Flos abelmoschi manihot, put into 80-100 DEG C of boiled water digestion 10-15 minute, put into 3-10 DEG C of cold water after pulling out immediately to soak and pull out again for 3-5 minute, then adopt prior art to be undertaken squeezing and filter and to obtain Flos abelmoschi manihot juice by the weight ratio of Flos abelmoschi manihot and pure water 1:1.
5., according to claim 1 vitamin d compositions, it is characterized in that described purple sweet potato powder is that light violet Rhizoma Dioscoreae esculentae is cut into 3-5mm lamellar, after temperature control 20-45 DEG C dries naturally, grind into 100-150 object powder.
6. a purposes for vitamin d compositions as claimed in claim 5, is characterized in that adult is 1 ~ 3 capsules daily, takes after half an hour after the meal for improving diabetes hereditary material stability.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510974074.XA CN105381313A (en) | 2015-10-08 | 2015-12-23 | Vitamin D composition and application thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2015106457937 | 2015-10-08 | ||
| CN201510645793 | 2015-10-08 | ||
| CN201510974074.XA CN105381313A (en) | 2015-10-08 | 2015-12-23 | Vitamin D composition and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105381313A true CN105381313A (en) | 2016-03-09 |
Family
ID=55414487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510974074.XA Pending CN105381313A (en) | 2015-10-08 | 2015-12-23 | Vitamin D composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105381313A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125348A (en) * | 2018-08-27 | 2019-01-04 | 杭州荣泽生物科技有限公司 | Umbilical cord mesenchymal stem cells combine application of the vitamin D in treatment diabetes medicament |
| CN111374281A (en) * | 2018-12-28 | 2020-07-07 | 江苏维乐益生食品科技有限公司 | Full-vitamin celery powder and preparation method thereof |
-
2015
- 2015-12-23 CN CN201510974074.XA patent/CN105381313A/en active Pending
Non-Patent Citations (4)
| Title |
|---|
| 孙双玲等: "维生素D3干预高糖负荷U937 细胞的差异蛋白质组分析", 《卫生研究》 * |
| 许曼音主编: "《糖尿病学》", 31 May 2010, 上海科学技术出版社 * |
| 郑成刚编: "《糖尿病自我调控》", 31 October 2004, 内蒙古科学技术出版社 * |
| 高志雄主编: "《运动+饮食+按摩：自我调养糖尿病》", 31 July 2013, 中国纺织出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125348A (en) * | 2018-08-27 | 2019-01-04 | 杭州荣泽生物科技有限公司 | Umbilical cord mesenchymal stem cells combine application of the vitamin D in treatment diabetes medicament |
| CN111374281A (en) * | 2018-12-28 | 2020-07-07 | 江苏维乐益生食品科技有限公司 | Full-vitamin celery powder and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101822749B (en) | Medicinal preparation for curing hypertension and hyperlipaemia and preparation method thereof | |
| KR101717893B1 (en) | Hyperlipemia-ameliorating agent, anemia-ameliorating composition, uric-acid-level-reducing composition, and foods and beverages | |
| WO2018145664A1 (en) | Anti-fatigue composition for use in improving endurance performance | |
| CN107080250A (en) | A kind of composition of auxiliary hyperglycemic, beverage and preparation method thereof | |
| JP2008174539A (en) | Healthy and functional food for obesity patient using purple-colored potato | |
| CN101491296A (en) | Natural feed additive and preparation method thereof | |
| CN107212256A (en) | A kind of meal replacement powder with function of blood sugar reduction and preparation method thereof | |
| CN107279296A (en) | A kind of formula food of suitable diabetes and preparation method thereof | |
| CN108783461A (en) | Ultrasonic wave added/combined-enzyme method synchronizes the method for extraction coix seed active constituent and its preparation method and application of microemulsion | |
| CN107580496B (en) | Anti-diabetic effect of gypenoside 75 | |
| CN107613998A (en) | Contain the prevention and treatment pharmaceutical composition or healthy food of the metabolic disease of Pleurotus ferulae water extract as active ingredient | |
| CN105381313A (en) | Vitamin D composition and application thereof | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN105410940B (en) | A kind of health food including xanthans | |
| TWI676473B (en) | Uses of poria cocos epidermis extract, poricoic acid a, and poricoic acid b in regulating blood glucose level | |
| CN111543638A (en) | Sea cucumber polysaccharide product with auxiliary blood sugar reducing effect and preparation method thereof | |
| CN110420270A (en) | A kind of functional composition containing camellia oil and fish oil and its application | |
| JP2001046019A (en) | Nutritive composition originated from citrus fruit | |
| AU2006347121B2 (en) | Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia | |
| CN102475712B (en) | Pharmaceutical composition used for preventing and treating diabetes and complications thereof | |
| KR101077546B1 (en) | A composition having antidiabetes activity consisting of Ligustrum fruit and red-ginseng Cheongkukjang powder | |
| CN106619972A (en) | Hirsutella hepiali chen et shen mycelium powder hypoglycemic capsule and preparation method and application thereof | |
| CN107296817B (en) | Use of Poria extract and temmoic acid for protecting muscle | |
| JP2016033125A (en) | Bioactivity after pulverizing mulberry twigs and bark having both of blood glucose elevation inhibitory action and blood pressure elevation inhibitory action | |
| CN105250919B (en) | It is a kind of for preventing and/or the Chinese medicine composition for treating liver disease and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160309 |
|
| RJ01 | Rejection of invention patent application after publication |